IP Library Granted Patent US 9,499,870
Granted Patent B2
US 9,499,870 · App. 14/498,629 · Granted Nov 22, 2016

Cell free DNA diagnostic testing standards

Inventors: Joshua Babiarz (Castro Valley, CA); Bernhard Zimmermann (San Mateo, CA)
Assignee: Natera, Inc.
C12Q1/6886C12N15/10C12Q1/6806C12Q1/6883C12Q2521/301C12Q2537/16C12Q2545/113C12Q2600/16C12Q2600/166Y10T436/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,870
App. No.
14/498,629
Granted
Nov 22, 2016
Kind
B2
Abstract

Embodiments of the invention include methods and compositions for producing proficiency testing standards for noninvasive prenatal genetic diagnostics and for the detection and monitoring of cancer. The compositions can include a plurality of different nucleosomal DNA fragments derived from either primary cells or cell lines. The amount of the different nucleosomal DNA fragments can be varied so as to simulate naturally occurring cell free DNA samples obtained from the blood of the pregnant woman or naturally occurring cell free DNA samples obtained from the blood of cancer patients.

Claims (26)

1. A cell-free nucleic acid diagnostic proficiency testing standard composition for analyzing non-invasive prenatal genetic tests, comprising

a set of at least two nucleosomal nucleic acid preparations,

wherein the nucleosomal nucleic acid preparations in the set have a quantity of a first nucleosomal nucleic acid preparation from a first cell line derived from a first individual and a quantity of a second nucleosomal nucleic acid preparation from a second cell line derived from a second individual,

wherein the first individual is a mother or father of the second individual and the first and second individuals have different copy numbers of at least one chromosome,

and wherein the quantity of the second nucleosomal nucleic acid preparation as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation is different for each of the nucleosomal nucleic acid preparations in the set.

2. The composition according to claim 1 , wherein the first nucleosomal nucleic acid preparation and the second nucleosomal nucleic acid preparation comprise mononucleosomal ladder fractions.

3. The composition according to claim 2 , wherein the first nucleosomal nucleic acid preparation further comprises dinucleosomal ladder fractions.

4. The composition of claim 1 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is less than 40% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

5. The composition of claim 1 , wherein the first nucleosomal nucleic acid preparation is obtained after apoptosis has been induced in the first cell line and/or the second nucleosomal nucleic acid preparation is obtained after apoptosis has been induced in the second cell line.

6. The composition of claim 1 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is less than 5% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

7. The composition of claim 1 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is between about 1% and about 70% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

8. The composition of claim 1 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is between about 4% and about 40% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

9. The composition of claim 1 , wherein the first individual or the second individual is aneuploid.

10. A method of making a cell-free nucleic acid diagnostic testing standard composition for analyzing non-invasive prenatal genetic tests, comprising

generating a set of at least two nucleosomal nucleic acid preparations,

wherein the nucleosomal nucleic acid preparations in the set are made by mixing a quantity of a first nucleosomal nucleic acid preparation derived from a first cell line derived from a first individual and a quantity of a second nucleosomal nucleic acid preparation derived from a second cell line derived from a second individual,

wherein the first individual is a mother or father of the second individual and the first and second individuals have different copy numbers of at least one chromosome,

and wherein the quantity of the second nucleosomal nucleic acid preparation as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation is different for each of the nucleosomal nucleic acid preparations in the set.

11. The method according to claim 10 , wherein the first nucleosomal nucleic acid preparation and the second nucleosomal nucleic acid comprise mononucleosomal ladder fractions.

12. The method according to claim 11 , wherein the first nucleosomal nucleic acid preparation further comprises dinucleosomal ladder fractions.

13. The method of claim 10 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is less than 40% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

14. The method of claim 10 , wherein the first nucleosomal nucleic acid preparation is obtained after apoptosis has been induced in the first cell line and/or the second nucleosomal nucleic acid preparation is obtained after apoptosis has been induced in the second cell line.

15. The method of claim 10 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is less than 5% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

16. The method of claim 10 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is between about 1% and about 70% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

17. The method of claim 10 , wherein the quantity of the second nucleosomal nucleic acid preparation in each of the nucleosomal nucleic acid preparations in the set is between about 4% and about 40% as a percentage of the quantity of the first nucleosomal nucleic acid preparation plus the quantity of the second nucleosomal nucleic acid preparation.

18. The method of claim 10 , wherein the first individual or the second individual is aneuploid.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 22, 2020
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: NATERA, INC.
Reel/Frame 052472/0712 →
SECURITY INTEREST Recorded Aug 8, 2017
From: NATERA, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 043482/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: BABIARZ, JOSHUA; ZIMMERMANN, BERNHARD
To: NATERA, INC.
Reel/Frame 034908/0502 →
Continuity (3)
Provisional Application 61883735 · Sep 27, 2013
Provisional Application 61978658 · Apr 11, 2014
Related Publication 20150147815A1 · May 28, 2015